Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment
bostonscientific.com

See what CB Insights has to offer

Investments

67

Portfolio Exits

18

Partners & Customers

10

Service Providers

1

About Boston Scientific

Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices. The company's products are used in a broad range of interventional medical specialties. The Neuromodulation Group provides the development of implantable, high-technology neurostimulation devices that include treatments for deafness and chronic pain.

Boston Scientific Headquarter Location

300 Boston Scientific Way

Marlborough, Massachusetts, 01752,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Boston Scientific

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Boston Scientific in 6 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

I

Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Bioelectronics

1,099 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

M

Medical Devices

4,284 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Boston Scientific Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Boston Scientific Rank

Latest Boston Scientific News

Y Combinator Names Surbhi Sarna Its First-Ever Partner For Healthcare And Biotech

Oct 26, 2021

Michele Beckwith Photography Inspired by the pandemic and recent portfolio successes including several public companies and newly-minted unicorns, Y Combinator is doubling down on bio startups with its first-ever partner focused fully on the area. The storied accelerator has tapped former nVision Medical founder and CEO Surbhi Sarna to serve as a group partner focused on bio. Sarna spent the past year as a visiting partner at Y Combinator. Sarna is taking the baton from YC managing director Jared Friedman, the former Scribd cofounder who has overseen YC’s growing bio portfolio in recent years, among other commitments. Her appointment gives Y Combinator 11 group partners for its upcoming winter batch. (Former Algolia founder and CEO Nicolas Dessaigne has also been promoted to group partner.) YC’s four visiting partners for the winter include new arrival Divya Bhat, until recently chief product officer of Virta Health. Sarna’s mission is straightforward: to help deepen and standardize YC’s playbook when it comes to bio and life sciences participants, all while supporting other entrepreneurs who may not fit the traditional biotech VC funding pipeline mold. Y Combinator first got involved in bio and healthcare in 2014, when Ginkgo Bioworks joined its summer batch after a push by Sam Altman and Paul Buchheit to include such companies, even without any domain expertise among YC’s partnership. The accelerator targeted entrepreneurs its partners saw as underserved by more traditional biotech investors, who often actively incubate and assemble veteran founding teams. Recommended For You Fewer stories like this “The idea that a recent PhD or postdoc could actually start their own successful therapeutics company was quite a radical idea at the time; it’s still not widely accepted,” Friedman says. At first, YC’s name and network were most valuable in helping to convince such fledgling entrepreneurs that it was okay to quit their academic posts or jobs, Friedman adds. Over time, investors flocking to its Demo Day began looking to write checks in the bio space, and new arrivals were able to turn to past batches for expertise. YC accepted its first therapeutics company in 2017. In its most recent Summer 2021 batch, YC admitted about 50 healthcare companies, 20 of them in “hardcore” therapeutics and 10 or so developing medical devices and diagnostics. Standouts so far include Ginkgo, which went public and now holds a market capitalization north of $25 billion; Solugen, which produces industrial chemicals from plants; Asher Bio, in immunotherapy cancer treatments; and Pardes, which recently filed to go public on the back of its antiviral drugs, including one for Covid-19. YC bio companies have raised a combined $7 billion to date, the organization says. Ginkgo Bioworks and its cofounders, pictured here in 2019, remain Y Combinator's runaway success in ... [+] biotech to date. Michael Prince/The Forbes Collection To get that number up to 75 or 100 companies in future batches, YC turned to Sarna, whom the partnership identified as similar to their favored bio profile. Sarna herself had been doubted for being too young and inexperienced to build nVision, a startup she founded at age 24 after a teenage ovarian cancer scare, that looked to manufacture devices that could detect the deadly disease in a woman’s fallopian tubes. “It took me a year and 50-plus meetings to raise my first $250,000 to go build a prototype,” she says. Sarna sold nVision to Boston Scientific in 2018 for $275 million, including earn-outs. To institutionalize YC’s bio program, Sarna will have to differentiate its process from the accelerator’s approach to software companies, many of which receive an acceptance or rejection decision in the same day. Instead, she says she’ll talk to physicians and other experts, dig into the documentation and check  if the science is real, or at least has the potential for further investigation. “I don’t believe in cutting corners when it comes to healthcare at all,” Sarna says. “You need to be really solid on what your reimbursement plan is, what the regulatory plan is, and how you prove and scientifically publish that the science you’re working on is right.” Y Combinator is also taking measures to structure its experience for companies with certain focuses. The accelerator will group together therapeutics batch members, for example, or synthetic biology ones, providing playbooks focused on key performance indicators, or KPIs, specific to bio and health companies against which they can measure themselves. Sarna is also forming a scientific advisory network to work with portfolio companies. Skeptics would point to Ginkgo as YC’s far-and-away biggest success in bio so far, and note that for its recent bigger crops of companies passing through its batches, it remains too early to tell just how such companies stack up against other bio portfolios, or even other focus groups within YC. Sarna and Friedman argue the firm has at least five unicorns, and Pardes’ pending offering will make three IPOs. A bigger concern, they say, is convincing high-caliber entrepreneurs that they can get enough value out of YC’s time-constrained program. Sarna plans to combat that by providing assistance as soon as companies are admitted, not just at the formal start date. “What I’m hoping is that by demo day we’re delivering a full package of not just, ‘these are great scientists working on great science,’ but they have their business model, and their story, their regulatory strategy, and their reimbursement strategy all sorted out,” Sarna says. Follow me on  Twitter  or  LinkedIn . Send me a secure  tip .

Boston Scientific Investments

67 Investments

Boston Scientific has made 67 investments. Their latest investment was in Nectero Medical as part of their Series C on September 9, 2021.

CBI Logo

Boston Scientific Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/1/2021

Series C

Nectero Medical

$19.5M

Yes

4

8/4/2021

Series A

Append Medical

$7.4M

Yes

4

3/5/2021

Corporate Minority

New Radiomedicine

Yes

1

9/21/2020

Corporate Minority - II

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/1/2021

8/4/2021

3/5/2021

9/21/2020

7/15/2020

Round

Series C

Series A

Corporate Minority

Corporate Minority - II

Series B

Company

Nectero Medical

Append Medical

New Radiomedicine

Subscribe to see more

Subscribe to see more

Amount

$19.5M

$7.4M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

4

1

10

10

Boston Scientific Portfolio Exits

18 Portfolio Exits

Boston Scientific has 18 portfolio exits. Their latest portfolio exit was RenovoRx on August 26, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/26/2021

IPO

$991

3

12/7/2020

Acq - Fin

1

5/12/2020

Divestiture

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/26/2021

12/7/2020

5/12/2020

00/00/0000

00/00/0000

Exit

IPO

Acq - Fin

Divestiture

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Boston Scientific Acquisitions

54 Acquisitions

Boston Scientific acquired 54 companies. Their latest acquisition was Baylis Medical Company on October 06, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/6/2021

Grant

$991

Acquired - II

2

9/21/2021

Series B

$991

$26.5M

Acquired

2

6/24/2021

Corporate Minority - II

$991

$63.48M

Acquired

8

3/8/2021

Acq - Fin - II

Subscribe to see more

$991

$99M

Subscribe to see more

10

3/3/2021

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

10/6/2021

9/21/2021

6/24/2021

3/8/2021

3/3/2021

Investment Stage

Grant

Series B

Corporate Minority - II

Acq - Fin - II

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Total Funding

$26.5M

$63.48M

$99M

$99M

Note

Acquired - II

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

2

8

10

10

Boston Scientific Partners & Customers

10 Partners and customers

Boston Scientific has 10 strategic partners and customers. Boston Scientific recently partnered with United Language Group on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/5/2021

Partner

United Language Group

United States

The Value of a Language Partner. The Power of Partnerships to Improve Lives Worldwide.

Both ULG and Boston Scientific understand the power of a great relationship and the immense work that a language service provider can facilitate worldwide .

1

3/5/2021

Licensor

ControlRad

United States

FDA Clears ControlRad’s ControlRad Select

In preparation for the commercialization efforts , ControlRad , Inc. has entered into an exclusive agreement with Boston Scientific Corp. to sell the ControlRad technology .

1

1/26/2021

Partner

IBM

United States

1

4/23/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/16/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/5/2021

3/5/2021

1/26/2021

4/23/2020

4/16/2020

Type

Partner

Licensor

Partner

Partner

Licensor

Business Partner

United Language Group

ControlRad

IBM

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

The Value of a Language Partner. The Power of Partnerships to Improve Lives Worldwide.

Both ULG and Boston Scientific understand the power of a great relationship and the immense work that a language service provider can facilitate worldwide .

FDA Clears ControlRad’s ControlRad Select

In preparation for the commercialization efforts , ControlRad , Inc. has entered into an exclusive agreement with Boston Scientific Corp. to sell the ControlRad technology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Boston Scientific Service Providers

1 Service Provider

Boston Scientific has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Boston Scientific Team

50 Team Members

Boston Scientific has 50 team members, including current Chief Executive Officer, Alissa Brandon PMP.

Name

Work History

Title

Status

John Abele

Founder

Current

Alissa Brandon PMP

Biocompatibles, Serica Technologies, and Tufts University

Chief Executive Officer

Current

Robert Zollars

Founder

Current

Art Butcher

Executive Vice President

Current

Dave Pierce

Biocompatibles, and U.S. Army

Executive Vice President

Current

Name

John Abele

Alissa Brandon PMP

Robert Zollars

Art Butcher

Dave Pierce

Work History

Biocompatibles, Serica Technologies, and Tufts University

Biocompatibles, and U.S. Army

Title

Founder

Chief Executive Officer

Founder

Executive Vice President

Executive Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.